Developer docs
API playgroundTry for free, no card

Search company profiles

Tegmine Therapeutics

Full company profile

uuid000562n

Namestring
Tegmine Therapeutics
Legal namestring
Tegmine Therapeutics
Websiteurl
tegminetx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Tegmine Therapeutics is a private, pre-clinical biotechnology company headquartered in San Francisco, California, with a research facility in South San Francisco's biotech corridor. The company develops antibody-based therapeutics that target glycoproteins — cell-surface structures characteristic of many aggressive solid cancers — with the goal of treating malignancies that lack effective targeted therapies. Its lead candidate class is built on proprietary chemistry around cancer-associated glycan modifications, an area the company describes as broadly underserved by current oncology biologics.

The company's central technology is the proprietary TegMiner™ platform, an engineered system for identifying unique cancer-specific epitopes arising from glycan modifications on glycoproteins and for generating monoclonal antibodies and antibody-drug conjugates (ADCs) against them. Pipeline products include glycoprotein-targeting antibodies intended to improve efficacy while reducing toxic side effects relative to conventional cancer therapies, and ADCs that pair these antibodies with cytotoxic payloads for currently untreatable cancers. In April 2022, Tegmine announced a collaboration with Alloy Therapeutics, under which Tegmine supplies immunogens and reagents while Alloy leads antibody discovery and validation, splitting the work along each party's core competencies in glycan targeting and antibody engineering.

Tegmine operates as a pre-revenue, partnership-driven biotech. The company has no disclosed funding rounds, investors, or revenue figures in the available data, though it offers equity compensation to employees and currently lists two open scientific positions (Research Associate in Antibody Discovery and Development; Scientist in Cell Biology) at the South San Francisco research site. Future commercialization is expected to flow through licensing agreements or co-development with pharmaceutical partners, leveraging CEO Jeff Bernstein's prior experience at Merck and Stemcentrx — including contribution to the approved V114 glycoconjugate vaccine — to advance candidates toward IND-enabling studies and eventual partnering.

Short descriptiontext

Tegmine Therapeutics is a private, pre-clinical biotech developing antibody therapeutics and antibody-drug conjugates that target glycoprotein modifications on solid tumors, using its proprietary TegMiner™ discovery platform and a partnership with Alloy Therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody therapeutics, glycoprotein targeting, cancer drug discovery, antibody-drug conjugates, oncology biologics
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development
TypeLicensing Royalties
Description

Pre-revenue biotech company developing novel antibody therapeutics for cancer treatment. Revenue model likely based on licensing deals, co-development partnerships, and eventual product commercialization through pharmaceutical partners.

tegminetx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tegmine Therapeutics develops antibody-based therapeutics that target glycoproteins, a hallmark of solid cancers. The company uses its proprietary TegMiner™ platform to discover unique cancer-specific epitopes on glycoproteins and to engineer novel monoclonal antibodies and antibody-drug conjugates (ADCs) aimed at treating solid cancers with high unmet medical need while reducing toxic side effects.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Tegmine Therapeutics is a biotechnology company operating with a single unified discovery platform called TegMiner™, which enables the identification of unique cancer epitopes on glycoproteins. The company's product portfolio consists of a pipeline of therapeutic candidates including glycoprotein-targeting antibodies and antibody-drug conjugates (ADCs), all developed through the TegMiner platform to target cancer-related glycan modifications. The platform serves as the foundational technology enabling development of the antibody-based therapeutic pipeline.

Product and service2 records
1Glycoprotein-Targeting Antibodies
CategoryOncology Biologics — Antibody Therapeutics
Description

Pre-clinical antibody therapeutic candidates developed on the TegMiner™ platform that target glycoproteins — a hallmark of solid cancers — to increase anti-tumor efficacy while reducing toxic side effects relative to conventional cancer therapies. Targeted at pharmaceutical and biotech partners for licensing or co-development.

2Antibody-Drug Conjugates (ADCs)
CategoryOncology Biologics — Antibody-Drug Conjugates
Description

Therapeutic ADC candidates that combine Tegmine's glycoprotein-targeting antibodies with cytotoxic payloads, intended to enable targeted delivery of cell-killing agents to solid tumors while sparing healthy tissue. Targeted at pharmaceutical and biotech partners for licensing or co-development.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-06
Description

Tegmine Therapeutics announced a collaboration with Alloy Therapeutics to develop antibody therapeutics targeting cancer-related glycan modifications. Under the agreement, Tegmine will produce immunogens and reagents while Alloy will lead antibody discovery and validation efforts. This partnership leverages each company's core competencies in glycan targeting and antibody discovery to advance novel cancer therapeutics.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing ADCs and immune-stimulating antibody conjugates for solid tumors. Highly comparable to Tegmine's glycoprotein-targeting ADC pipeline and oncology-focused discovery model, though operating at a more advanced clinical stage.

TypeDirect peer
Description

ADC-focused oncology company developing antibody-drug conjugates for solid tumors. Direct comparability in modality (ADCs) and therapeutic area (solid tumor oncology), with overlapping glycoprotein/antibody discovery capabilities.

TypeDirect peer
Description

Pre-clinical and early-clinical biotech developing ADCs and antibody therapeutics for cancer. Comparable platform approach and oncology focus, useful as a peer for capital-efficient pre-clinical ADC builders.

TypeDirect peer
Description

Clinical-stage ADC company with proprietary platforms (Dolasynthen, Immunosynthen). Strong direct comparability on ADC modality and oncology indications, despite being at a more advanced stage than Tegmine.

TypeBroad incumbent
Description

Pioneer in ADC development (now part of AbbVie) with multiple approved and clinical-stage ADCs. Represents the incumbent benchmark against which Tegmine's emerging ADC pipeline will be compared for licensing and partnership value.

TypeBroad incumbent
Description

Global ADC leader (acquired by Pfizer in 2023) with multiple approved oncology ADCs. Major incumbent that defines the strategic and competitive landscape for ADC-focused startups like Tegmine.

TypeBroad incumbent
Description

Japanese pharma leader in next-generation ADCs (Enhertu, Datroway). Sets the bar for ADC efficacy and global partnership economics, making it the most relevant incumbent peer for an ADC startup.

TypeBroad incumbent
Description

Pioneer in monoclonal antibody therapeutics (Darzalex, with Janssen). Broad incumbent whose antibody discovery and licensing playbook is the model against which Tegmine's mAb pipeline should be benchmarked.

9Mythic Therapeutics
TypeEmerging player
Description

Pre-clinical/early-clinical biotech developing antibody therapeutics for solid tumors using a proprietary platform. Highly comparable stage and platform approach to Tegmine, useful as a peer for early-stage antibody oncology developers.

TypeEmerging player
Description

Clinical-stage oncology biotech developing engineered antibody-based therapeutics (PREDATOR platform) for solid tumors. Comparable in therapeutic area (solid tumor oncology) and platform-driven antibody approach, despite being at a more advanced stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tegmine Therapeutics

Oncology Biopharmaceuticalstegminetx.com

Tegmine Therapeutics is a private, pre-clinical biotech developing antibody therapeutics and antibody-drug conjugates that target glycoprotein modifications on solid tumors, using its proprietary TegMiner™ discovery platform and a partnership with Alloy Therapeutics.

What Tegmine Therapeutics does

Tegmine Therapeutics is a private, pre-clinical biotechnology company headquartered in San Francisco, California, with a research facility in South San Francisco's biotech corridor. The company develops antibody-based therapeutics that target glycoproteins — cell-surface structures characteristic of many aggressive solid cancers — with the goal of treating malignancies that lack effective targeted therapies. Its lead candidate class is built on proprietary chemistry around cancer-associated glycan modifications, an area the company describes as broadly underserved by current oncology biologics.

The company's central technology is the proprietary TegMiner™ platform, an engineered system for identifying unique cancer-specific epitopes arising from glycan modifications on glycoproteins and for generating monoclonal antibodies and antibody-drug conjugates (ADCs) against them. Pipeline products include glycoprotein-targeting antibodies intended to improve efficacy while reducing toxic side effects relative to conventional cancer therapies, and ADCs that pair these antibodies with cytotoxic payloads for currently untreatable cancers. In April 2022, Tegmine announced a collaboration with Alloy Therapeutics, under which Tegmine supplies immunogens and reagents while Alloy leads antibody discovery and validation, splitting the work along each party's core competencies in glycan targeting and antibody engineering.

Tegmine operates as a pre-revenue, partnership-driven biotech. The company has no disclosed funding rounds, investors, or revenue figures in the available data, though it offers equity compensation to employees and currently lists two open scientific positions (Research Associate in Antibody Discovery and Development; Scientist in Cell Biology) at the South San Francisco research site. Future commercialization is expected to flow through licensing agreements or co-development with pharmaceutical partners, leveraging CEO Jeff Bernstein's prior experience at Merck and Stemcentrx — including contribution to the approved V114 glycoconjugate vaccine — to advance candidates toward IND-enabling studies and eventual partnering.

Tegmine Therapeutics firmographics

Firmographics
Name
Tegmine Therapeutics
Legal name
Tegmine Therapeutics
Website
https://tegminetx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Tegmine Therapeutics is a private, pre-clinical biotech developing antibody therapeutics and antibody-drug conjugates that target glycoprotein modifications on solid tumors, using its proprietary TegMiner™ discovery platform and a partnership with Alloy Therapeutics.
Ownership category
akta.pro rank

Tegmine Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody therapeutics
  • Glycoprotein targeting
  • Cancer drug discovery
  • Antibody-drug conjugates
  • Oncology biologics

Where Tegmine Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Tegmine Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Development: Pre-revenue biotech company developing novel antibody therapeutics for cancer treatment. Revenue model likely based on licensing deals, co-development partnerships, and eventual product commercialization through pharmaceutical partners.

Go-to-market motion1 record

Marketing channels1 record

Tegmine Therapeutics product offering

Product offering

Core offering

Tegmine Therapeutics develops antibody-based therapeutics that target glycoproteins, a hallmark of solid cancers. The company uses its proprietary TegMiner™ platform to discover unique cancer-specific epitopes on glycoproteins and to engineer novel monoclonal antibodies and antibody-drug conjugates (ADCs) aimed at treating solid cancers with high unmet medical need while reducing toxic side effects.

Product overview

Tegmine Therapeutics is a biotechnology company operating with a single unified discovery platform called TegMiner™, which enables the identification of unique cancer epitopes on glycoproteins. The company's product portfolio consists of a pipeline of therapeutic candidates including glycoprotein-targeting antibodies and antibody-drug conjugates (ADCs), all developed through the TegMiner platform to target cancer-related glycan modifications. The platform serves as the foundational technology enabling development of the antibody-based therapeutic pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • Glycoprotein-Targeting Antibodies Pre-clinical antibody therapeutic candidates developed on the TegMiner™ platform that target glycoproteins — a hallmark of solid cancers — to increase anti-tumor efficacy while reducing toxic side effects relative to conventional cancer therapies. Targeted at pharmaceutical and biotech partners for licensing or co-development.
  • Antibody-Drug Conjugates (ADCs) Therapeutic ADC candidates that combine Tegmine's glycoprotein-targeting antibodies with cytotoxic payloads, intended to enable targeted delivery of cell-killing agents to solid tumors while sparing healthy tissue. Targeted at pharmaceutical and biotech partners for licensing or co-development.

Companies that use Tegmine Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Tegmine Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Tegmine Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alloy TherapeuticscoreStrategic or Co-development Partner · 6 April 2022Tegmine Therapeutics announced a collaboration with Alloy Therapeutics to develop antibody therapeutics targeting cancer-related glycan modifications. Under the agreement, Tegmine will produce immunogens and reagents while Alloy will lead antibody discovery and validation efforts. This partnership leverages each company's core competencies in glycan targeting and antibody discovery to advance novel cancer therapeutics.

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Tegmine Therapeutics competitors and assessment

Company assessment

Direct peers

  • Bolt Biotherapeutics: Clinical-stage biotech developing ADCs and immune-stimulating antibody conjugates for solid tumors. Highly comparable to Tegmine's glycoprotein-targeting ADC pipeline and oncology-focused discovery model, though operating at a more advanced clinical stage.
  • Pyxis Oncology: ADC-focused oncology company developing antibody-drug conjugates for solid tumors. Direct comparability in modality (ADCs) and therapeutic area (solid tumor oncology), with overlapping glycoprotein/antibody discovery capabilities.
  • ProfoundBio: Pre-clinical and early-clinical biotech developing ADCs and antibody therapeutics for cancer. Comparable platform approach and oncology focus, useful as a peer for capital-efficient pre-clinical ADC builders.
  • Mersana Therapeutics: Clinical-stage ADC company with proprietary platforms (Dolasynthen, Immunosynthen). Strong direct comparability on ADC modality and oncology indications, despite being at a more advanced stage than Tegmine.

Broad incumbents

  • ImmunoGen (AbbVie): Pioneer in ADC development (now part of AbbVie) with multiple approved and clinical-stage ADCs. Represents the incumbent benchmark against which Tegmine's emerging ADC pipeline will be compared for licensing and partnership value.
  • Seagen (Pfizer): Global ADC leader (acquired by Pfizer in 2023) with multiple approved oncology ADCs. Major incumbent that defines the strategic and competitive landscape for ADC-focused startups like Tegmine.
  • Daiichi Sankyo: Japanese pharma leader in next-generation ADCs (Enhertu, Datroway). Sets the bar for ADC efficacy and global partnership economics, making it the most relevant incumbent peer for an ADC startup.
  • Genmab: Pioneer in monoclonal antibody therapeutics (Darzalex, with Janssen). Broad incumbent whose antibody discovery and licensing playbook is the model against which Tegmine's mAb pipeline should be benchmarked.

Emerging players

  • Mythic Therapeutics: Pre-clinical/early-clinical biotech developing antibody therapeutics for solid tumors using a proprietary platform. Highly comparable stage and platform approach to Tegmine, useful as a peer for early-stage antibody oncology developers.
  • Werewolf Therapeutics: Clinical-stage oncology biotech developing engineered antibody-based therapeutics (PREDATOR platform) for solid tumors. Comparable in therapeutic area (solid tumor oncology) and platform-driven antibody approach, despite being at a more advanced stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Tegmine Therapeutics social profiles

Digital presence

Tegmine Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tegmine Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Tegmine Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tegmine Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tegmine Therapeutics

What does Tegmine Therapeutics do?

Tegmine Therapeutics develops antibody-based therapeutics that target glycoproteins, a hallmark of solid cancers. The company uses its proprietary TegMiner™ platform to discover unique cancer-specific epitopes on glycoproteins and to engineer novel monoclonal antibodies and antibody-drug conjugates (ADCs) aimed at treating solid cancers with high unmet medical need while reducing toxic side effects.

Is Tegmine Therapeutics a public or private company?

Tegmine Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Tegmine Therapeutics founded?

Tegmine Therapeutics was founded in 2017. It employs 1 to 10 people.

Where is Tegmine Therapeutics based?

Tegmine Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Tegmine Therapeutics make money?

One revenue line is on record: biopharmaceutical Development.

Who are Tegmine Therapeutics's main competitors?

Direct peers on record are Bolt Biotherapeutics, Pyxis Oncology, ProfoundBio and Mersana Therapeutics. Broad incumbents are ImmunoGen (AbbVie), Seagen (Pfizer), Daiichi Sankyo and Genmab. Emerging players are Mythic Therapeutics and Werewolf Therapeutics.

Does Tegmine Therapeutics have an API?

No public API is recorded for Tegmine Therapeutics.

What industry is Tegmine Therapeutics in?

Tegmine Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTegMine Therapeutics Enters Collaboration with Boehringer Ingelheim to Advance Novel 2-Factor Antibody System for CancerTegMine Therapeutics announced a strategic R&D collaboration with Boehringer Ingelheim to develop ADC therapeutics using its proprietary 2-Factor Antibody System for cancer treatment. The partnership focuses on an initial program targeting a clinically validated antigen, with potential expansion to two additional targets, leveraging TegMine's platform that identifies tumor-specific glycan epitopes. Under the agreement, TegMine will receive upfront payments, research funding, milestone payments, and royalties on net sales, while Boehringer Ingelheim gains global development and commercial rights for each target.Business Wire BlogTegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor TreatmentTegmine Therapeutics announced an investment and collaboration with Alloy Therapeutics to advance antibody therapeutics targeting cancer-associated glycan modifications. Tegmine will generate immunogens and screening reagents, while Alloy will lead antibody discovery and hit validation. The partnership aims to develop more selective cancer treatments for solid tumors.Business Wire BlogTegmine Therapeutics Announces Collaboration with Alloy Therapeutics to Advance Solid Tumor TreatmentTegmine Therapeutics announced an investment from Alloy Therapeutics and a strategic collaboration to accelerate the development of antibody therapeutics targeting solid tumors. Under the agreement, Tegmine will generate immunogens and screening reagents while Alloy leads antibody discovery and hit validation efforts. This partnership combines Tegmine's proprietary cell platforms with Alloy's antibody discovery technologies to address unmet needs in cancer treatment.